title: [Occurrence of vitiligo in a patient with ankylosing spondylitis receiving adalimumab].
authors: Pôle de recherche, centre d'investigation clinique biothérapie Inserm CBT-506, CHRU, 2, place Saint-Jacques, 25000 Besançon, France; Pôle PACTE (pathologies aiguës chroniques transplantation éducation), rhumatologie, CHRU hôpital Jean-Minjoz, boulevard Fleming, 25000 Besançon, France; Département universitaire de thérapeutique et UPRES EA 4266 « agents pathogènes et inflammation», SFR FED 4234, université de Franche-Comté, 25000 Besançon, France. Electronic address: etoussirot@chu-besancon.fr.
authors: E
authors: E
authors: Toussirot
authors: D
authors: D
authors: Salard
authors: M-P
authors: MP
authors: Algros
authors: F
authors: F
authors: Aubin
mesh_terms: D000068879:Adalimumab; D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D017209:Apoptosis / Q000502:physiology; D015984:Causality; D004198:Disease Susceptibility; D006801:Humans; D008297:Male; D008544:Melanocytes / Q000473:pathology; D013167:Spondylitis, Ankylosing / Q000150:complications / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000502:physiology; D014820:Vitiligo / Q000139:chemically induced* / Q000175:diagnosis / Q000473:pathology
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab